TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

34 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

29 studies on the map

Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency — University of Alabama at Birmingham, BirminghamUblituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis — Northwestern Memorial Hospital, ChicagoSafety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial — AARA Clinical Research, GlendaleDalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis — MGH Institute of Health Professions, BostonDapagliflozin in Active Lupus Nephritis — Massachusetts General Hospital, BostonThe Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM) — UCSF Airway Clinical Research Center, San FranciscoMechanism(s) of Airflow Limitation During Exacerbation of Asthma — Arthur F Gelb Medical Corporation, LakewoodTrial of Belimumab in Early Lupus — Feinstein Institute, ManhassetPRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis — Purushotham & Akther Kotha MD, Inc., La Mesa45th Multicenter Airway Research Collaboration — MetroHealth, ClevelandLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping — Mayo Clinic, ScottsdaleHome Based Infusions for Ocrelizumab — Amerita, CentennialA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) — GSK Investigational Site, AnnistonCHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma — Affinia healthcare, 2220 Lemp Ave, St LouisProspective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod — University of Colorado Anschutz Medical Campus, AuroraSafety of the Herpes Zoster Subunit Vaccine in Lupus — NYU Langone Health, New YorkStudy of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis — Johns Hopkins University, BaltimoreCompare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators — The University of Tennessee Graduate School of Medicine, KnoxvilleVentilation and Perfusion in Asthmatics — University of Miami - Converge Miami, MiamiGlucose Consumption in MS Using [F-18]FDG-PET — Brigham & Women's Hospital, BostonSilodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis — Atlantic Health, MorristownProspective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users — Research Site, Las VegasOcrelizumab Discontinuation in Relapsing Multiple Sclerosis — Yale School of Medicine, New HavenViral Infection in Asthma (VIA) Study — University of Virginia, CharlottesvilleFeasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD — University of Tennessee Medical Center, KnoxvilleMeasuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma — The University of Pittsburgh Asthma Institute at UPMC, PittsburghA Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 — Local Institution - 0001, FarmingtonIndividualizing Treatment for Asthma in Primary Care (Full Study) — DARTNet Institute, AuroraA Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. — University of Alabama at Birmingham - School of Medicine- Site Number : 8400003, Birmingham